Skip to Content

Markets
Technicals
Companies
Earnings
Close-Up
Themes

News

Market and company headlines

AARDAll

Loading

A personal project for following the US markets. Free, ad-free and open source.

Weekly Recap

Every Sunday morning: the week's earnings behind you and the calendar ahead, in one email.

Get It by Email

Market

Markets
Companies
Stock Screener
Macro
Earnings
Technical Analysis
Calendar
Compare
Thematic Lists
Famous Investors

Reading

Guide
Close-Up
Community
News
Brief Archive
Glossary
Tax Calculator
RSS

Account

Watchlist
My Posts
Bell Report
Portfolio
Settings
Privacy

© 2026 Opening BellPrivacy About What's New ContactNot Investment AdviceAhmet Akyapı

Markets Earnings Close-Up Menu

Nasdaq 100 · QQQ721.22+ 1.27%S&P 500 · SPY769.93+ 0.60%Dow Jones · DIA523.42+ 0.09%Russell 2000 · IWM280.07+ 1.11%

Aardvark Therapeutics stock surges as FDA lifts clinical hold
Investing.com -- Aardvark Therapeutics Inc (NASDAQ:AARD) shares jumped 21% in after-hours trading Thursday after the FDA lifted the clinical hold on the company's ARD-101 drug candidate for the treatment of hyperphagia in Prader-Willi Syndrome.
Yahoo17:574 Days AgoAARD

16:00-18:00Oct 222 Stories

Postmarket Movers: After-Hours Gainers and Decliners
Notable after-hours gainers included LUCD, AARD, RNG and RHI; decliners included SHFS, SDST and DECK after the US session close.
ChartMill17:00AARD
Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data
Clinical development of ARD-101 for hyperphagia in Prader-Willi Syndrome (PWS) may resume Aardvark will host a webcast to review available dataset from the terminated Phase 3 HERO trial and OLE trial on Friday, October 23, 2026, at 8:00 a.m. EST SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of P
Yahoo16:05AARD

11:00Oct 211 Story

All You Need to Know About Aardvark Therapeutics, Inc. (AARD) Rating Upgrade to Buy
Aardvark Therapeutics, Inc. (AARD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Yahoo11:00AARD

02:00Oct 191 Story

HC Wainwright & Co. Maintains Neutral on Aardvark Therapeutics, Lowers Price Target to $4
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Aardvark Therapeutics (NASDAQ:AARD) with a Neutral and lowers the price target from $6 to $4.
Benzinga02:56AARD

10:00Oct 121 Story

Prader-Willi Syndrome Market to Expand by 2036 as New Therapeutic Opportunities Address Unmet Clinical Needs | DelveInsight
Recently published Prader-Willi Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Prader-Willi syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Yahoo10:31

16:00Oct 21 Story

Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that on October 1, 2026, one new employee was granted an inducement award consisting of a stock option to purchase 60,000 shares of common stock. The option was granted pursuant to the Aardvark Therapeut
Yahoo16:05AARD

05:00Sep 241 Story

RBC Capital Reiterates Sector Perform on Aardvark Therapeutics, Maintains $6 Price Target
RBC Capital analyst Brian Abrahams reiterates Aardvark Therapeutics (NASDAQ:AARD) with a Sector Perform and maintains $6 price target.
Benzinga05:27AARD

12:00Aug 111 Story

Aardvark Therapeutics Q2 EPS $(0.66) Beats $(0.91) Estimate
Aardvark Therapeutics (NASDAQ:AARD) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate of $(0.91) by 27.47 percent. This is unchanged from the same period last year.
Benzinga12:55AARD